The Winning Combination: Avanir’s Nuedexta Finally Cleared For Emotional Incontinence
Executive Summary
Once feared for potentially harmful cardiovascular effects, Avanir Pharmaceuticals Inc.’s Nuedexta has become the first drug to gain FDA approval for treatment of the involuntary emotional disorder “pseudobulbar affect,” with no black box warning.
You may also be interested in...
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
Institutional Setting Becomes Marketing Bedrock For Avanir’s “Laughing” Drug
Since obtaining FDA approval of Neudexta in pseudobulbar affect in October 2010, Avanir has seen sales grow incrementally, but continues to learn about opportunities in the emotional incontinence market.
Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
Letters from Sen. Kohl and Reps. Waxman, Pallone and DeGette are reminiscent of the recent uproar over pricing for KV's Makena.